Top Markets
Coin of the day
Daiichi Sankyo Company, Limited Daiichi Sankyo Company, Limited

Daiichi Sankyo Company, Limited

4568
Classement en actions #779
Daiichi Sankyo Company, Limited is a global pharmaceutical enterprise actively... Daiichi Sankyo Company, Limited is a global pharmaceutical enterprise actively involved in the research, development, manufacturing, importation, marketing, and distribution of a diverse array of medicinal products worldwide. Its extensive product lineup addresses numerous therapeutic areas. In oncology, key offerings include trastuzumab deruxtecan, an anti-HER2 antibody drug conjugate, alongside treatments like Gefitinib for malignant tumors, Bicalutamide for prostate cancer, and Tamoxifen, an anti-breast cancer agent. For pain management, the company provides mirogabalin and loxoprofen (an anti-inflammatory analgesic). Diabetes treatments feature teneligliptin/canagliflozin and teneligliptin, with colesevelam serving dual purposes for hypercholesterolemia and type 2 diabetes. Other notable prescription drugs include lacosamide (an anti-epileptic), prasugrel (an antiplatelet), denosumab (for osteoporosis and bone disorders), edoxaban (an anticoagulant), esomeprazole (for ulcer treatment), memantine (for Alzheimer's disease), and laninamivir (for influenza). The company also supplies olmesartan (an antihypertensive), levofloxacin (an antibacterial), pravastatin (for hypercholesterolemia), Silodosin (for dysuria), and ferric carboxymaltose/iron sucrose injections for anemia. Beyond prescription medications, Daiichi Sankyo markets popular consumer health brands such as Lulu (a combination cold remedy), Loxonin S (an antipyretic/anti-inflammatory painkiller), Transino (for melasma and skin improvement), Minon (skincare), and the oral care lines Breath Labo and Clean Dental. The company further contributes to public health with various vaccines, including adsorbed cell culture-derived influenza, influenza HA, measles-rubella combined, and mumps vaccines. Its operations also extend beyond human pharmaceuticals to include veterinary drugs, cosmetics, medical equipment, food products, drinking water, and the production of active pharmaceutical ingredients (APIs) and intermediates. Daiichi Sankyo is collaborating with Guardant Health on the development of Guardant360 CDx, a companion diagnostic for Enhertu, specifically for advanced metastatic non-small cell lung cancer. Founded in 1899, the company is headquartered in Tokyo, Japan.
Prix de l'action
$17.82
Dernière synchronisation: 2026-09-11
Capitalisation boursière
$32.43B
Changement (1 jour)
0.83%
Changement (1 an)
-25.31%
Pays
JP
Échange Daiichi Sankyo Company, Limited (4568)

Catégorie

Ratio P/E pour Daiichi Sankyo Company, Limited (4568)
Ratio P/E au September 2026 TTM : 21.74
Selon les derniers rapports financiers et le cours de l'action de Daiichi Sankyo Company, Limited, le ratio P/E actuel (TTM) est de 21.74. À la fin de l’année 2024, le P/E de l’entreprise était de 44.58.
Historique du ratio P/E pour Daiichi Sankyo Company, Limited de 2000 à 2026
Ratio P/E à la fin de chaque année
Année Ratio P/E Changez
2026 (TTM) 21.74 -3.43%
2025 22.51 -49.50%
2024 44.58 -47.34%
2023 84.66 10.38%
2022 76.70 -6.85%
2021 82.34 120.64%
2020 37.32 -2.53%
2019 38.29 -0.84%
2018 38.61 22.65%
2017 31.48 50.17%
2016 20.96 403.01%
2015 4.17 -79.24%
2014 20.08 9.51%
2013 18.33 -82.07%
2012 102.24 534.14%
2011 16.12 -45.26%
2010 29.45 -643.67%
2009 -5.42 -124.90%
2008 21.76 -35.05%
2007 33.50 49.10%
2006 22.47 0.07%
2005 22.45 9.57%
2004 20.49 -2.12%
2003 20.94 -26.72%
2002 28.57 -7.80%
2001 30.99 81.88%
2000 17.04 0.00%
Ratio P/E pour des entreprises similaires ou concurrentes
Entreprise P/E Ratio Différence du P/E Ratio Pays
38.79 78.44%
US
30.73 41.39%
US
72.23 232.29%
US
22.25 2.35%
CH
117.27 439.49%
US
Comment lire un P/E ratio ?

Le ratio Prix/Bénéfice (P/E Ratio) mesure la relation entre le cours de l'action d'une entreprise et ses bénéfices par action.
Un P/E bas mais positif indique une entreprise qui génère des bénéfices élevés par rapport à sa valorisation et qui pourrait être sous-évaluée. Un P/E négatif élevé (proche de 0) indique des pertes importantes.

Les entreprises avec un P/E supérieur à 30 ou négatif sont généralement considérées comme des "actions de croissance", ce qui signifie que les investisseurs s'attendent à ce qu'elles se développent ou deviennent rentables.

Les entreprises avec un P/E positif inférieur à 10 sont généralement considérées comme des "actions de valeur", car elles sont déjà très rentables mais avec peu de potentiel de croissance.